Knight Therapeutics (GUD.TO) Osake Kurssi
Knight Therapeutics Kurssi
Liikevaihto on kasvanut 98,0 % vuodessa viimeisten 10 vuoden aikana 371,30 M CAD:een. Osakekohtainen tulos on laskenut 32,6 % vuodessa viimeisten 10 vuoden aikana. Knight Therapeuticsn nettomarginaali on nyt 1,2 %, laskenut 21,1 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 8,16 CAD, eli ali nykyhintaa 29,7 %. 10 analyytikosta 8 suosittaa ostoa — kokonaiskonsensus on Osta.
Knight Therapeutics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Knight Therapeutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Knight Therapeutics -osakkeesta
The business model of Knight Therapeutics Inc. is focused on acquiring or in-licensing innovative pharmaceutical products and commercializing them in Canada and other global markets. Knight's strategy involves partnering with established pharmaceutical companies or academic institutions to access a diverse range of therapeutics and medical devices. By focusing on products that are either proven or have a high probability of regulatory approval, Knight aims to bring innovative treatments to patients and generate sustainable revenue growth. With its expertise in regulatory affairs, marketing, and distribution, Knight Therapeutics Inc. aims to optimize the value of its portfolio and deliver long-term value to shareholders.
Knight Therapeutics Inc is primarily active in the pharmaceutical industry. As a Canadian specialty pharmaceutical company, Knight Therapeutics focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and international markets. With a diverse portfolio, the company primarily operates in areas such as intellectual property-protected medicines, biotechnology products, and specialty pharmaceuticals. Knight Therapeutics strives to collaborate with global partners to bring novel therapies to patients, contributing to improved healthcare outcomes. Through its activities in the pharmaceutical industry, Knight Therapeutics aims to address unmet medical needs and provide innovative solutions for patients worldwide.
The main competitors of Knight Therapeutics Inc in the market include other pharmaceutical companies such as Valeo Pharma Inc, Cipher Pharmaceuticals Inc, and Crescita Therapeutics Inc.
Knight Therapeutics Inc. is a leading Canadian specialty pharmaceutical company established in 2014. Headquartered in Montreal, Quebec, Knight focuses on acquiring and commercializing innovative pharmaceutical products for the Canadian and international markets. With a mission to improve patient care by providing novel treatment options, Knight Therapeutics collaborates with global partners to bring cutting-edge therapies to market. The company's portfolio includes a diverse range of therapeutic areas such as oncology, mental health, and rare diseases. Known for its strategic management and growth-oriented approach, Knight Therapeutics is committed to delivering high-quality pharmaceuticals that address unmet medical needs and enhance healthcare outcomes.
Some significant milestones achieved by Knight Therapeutics Inc include expanding its product portfolio through strategic licensing agreements, successfully completing several clinical trials, and securing regulatory approvals for its pharmaceutical products in various markets. The company has also demonstrated strong financial performance, achieving consistent revenue growth and generating positive cash flow. Knight Therapeutics Inc has established partnerships with world-class pharmaceutical companies to leverage their expertise and expand its global reach. Furthermore, the company has made notable progress in advancing its pipeline of innovative therapies, aimed at addressing unmet medical needs and improving patient outcomes.
Knight Therapeutics Inc is primarily present in Canada, where it is headquartered in Quebec. As a specialty pharmaceutical company, Knight Therapeutics focuses on acquiring, developing, and commercializing innovative prescription drugs. With a strategic focus on Canada, the company also operates in other regions, including the United States and select European countries. As Knight Therapeutics continues to expand its presence and partnerships in the pharmaceutical industry, it aims to bring innovative therapies to patients worldwide.
Knight Therapeutics Inc represents values of integrity, innovation, and collaboration. With a corporate philosophy focused on delivering innovative pharmaceutical solutions, Knight Therapeutics is committed to improving patient outcomes and making a positive impact on global health. The company prioritizes ethical business practices, ensuring transparency and reliability in all its operations. Knight Therapeutics Inc emphasizes building strong partnerships with healthcare professionals and stakeholders to achieve shared goals. By consistently upholding its values and corporate philosophy, Knight Therapeutics Inc strives to be a trusted leader in the pharmaceutical industry.
Analyytikot asettavat tällä hetkellä Knight Therapeutics-osakkeelle keskimääräisen tavoitehinnan 8,09 CAD (mediaani: 8,16 CAD), mikä merkitsee −30,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.
10 analyytikkoa arvioi tällä hetkellä Knight Therapeutics-osaketta: 8 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Knight Therapeutics-yhtiöltä 552,23 M CAD liikevaihtoa ja 0,14 CAD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Knight Therapeutics-osake noteerataan hintaan 7,32 EUR (11,60 CAD).
Knight Therapeutics-osake (GUD.TO) on listattuna 4 pörssissä, muun muassa: Toronto (GUD.TO), Frankfurt (04K.F), München (04K.MU).
Knight Therapeutics Inc is a Canadian biopharmaceutical company that specializes in the development and marketing of innovative medicines. The company focuses on five main areas: infectious diseases, pain management, oncology, ophthalmology, and neuropsychiatric disorders. It works closely with leading research institutes and companies to find innovative approaches for these diseases and improve treatment options. Knight Therapeutics offers medication for life-threatening infections such as HIV, hepatitis, and tuberculosis, as well as tailored pain medications. It also develops therapies for cancer treatment, eye diseases, and neuropsychiatric disorders. Overall, Knight Therapeutics specializes in developing and marketing innovative medicines, working with research institutes and having a strong presence in the North American market. Its goal is to improve the lives of millions of people worldwide and contribute to medical research and development.
odotettu liikevaihto Knight Therapeutics on 552,23 M CAD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Knight Therapeutics on 14,00 M CAD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Knight Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä 84,07. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Knight Therapeutics-osakkeen arvostusta.
Knight Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,13. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Knight Therapeutics-osakkeen arvostuskennuslukuna.
Knight Therapeutics:n Eulpool-laatuscore on 6/10.
Knight Therapeutics:n ISIN on CA4990531069. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Knight Therapeutics:n WKN on A1XE7A. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Knight Therapeutics:n ticker on GUD.TO. Tämä pörssinoteeraus käytetään Knight Therapeutics-osakkeiden kauppaan pörssissä.
Knight Therapeutics osake
Knight Therapeutics vertaisryhmä
Knight Therapeutics Ticker
Knight Therapeutics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Knight Therapeutics:sta
Meidän osakeanalyysimme Knight Therapeutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Knight Therapeutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: